nective tissue diseases, malignancies, autoimmune diseases, bone marrow or organ transplantation, and radiotherapy) are required for a firm diagnosis [3] .
COP presents as an inflammatory disease. Usually serum inflammatory markers are elevated, and bronchoalveolar lavage fluid (BAL-f) shows an increased proportion of lymphocytes, neutrophils and eosinophils [4, 5] .
The cytokine profile in the BAL-f of COP patients is characterized by elevated levels of cytokines mediated by the T-helper 1 response, such as interleukin-18 (IL-18), interleukin-12 (IL-12) and macrophage inflammatory protein [6] . However, it has been suggested that mainly alveolar macrophages are involved in the pathogenic process in COP [7] . They exhibit increase expression of interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), fibronectin, tumor necrosis factor alpha (TNFα) and its soluble receptors sTNFR1/2, interferon gamma inducible protein 10, granulocyte-macrophage colony stimulating factor (GM-CSF) and chemokine (C-C motif) ligand 18 (CCL18) [8] [9] [10] [11] [12] [13] . Additionally, factors involved in apoptosis and tissue remodeling play a major role in the pathogenesis of COP [14] [15] .
The aim of this study was to assess the concentration of selected cytokines in the serum and BAL-f of COP patients and to investigate any correlations between these parameters and the patients' response to treatment with clarithromycin (CAM).
The study was supported by National Tuberculosis and Lung Disease Research Institute grant No. 7.3. The local bioethics committee approved the study, and the participants signed informed consent.
Material and Methods
From 2004 to 2014, 26 patients with COP (18 women and 8 men, mean age 56.46 ± 8.83 years; range 39-71 years), were enrolled in this study. All the patients were evaluated regarding their concomitant diseases, use of medicines, symptoms and the duration of the symptoms. Routine blood and urine tests, along with microbiological, mycological and immunological examinations of bronchoalveolar lavage were performed.
The presence of connective tissue disease symptoms, antinuclear antibodies, antineutrophil cytoplasmic antibodies, rheumatoid factor were also tested for, and serological tests were carried out for Mycoplasma pneumoniae, Chlamydia pneumoniae and Legionella pneumophila. In selected cases tests for cytomegalovirus, influenza and parainfluenza virus, respiratory syncytial virus, hepatitis virus B and C were carried out. Chest X-rays and high resolution computed tomography (HRCT) scans, ultrasound examinations of the abdomen and thyroid gland and pulmonary function tests were also performed on all the patients.
The following criteria were required for a COP diagnosis: pulmonary infiltration suggesting organizing pneumonia in radiological examinations, characteristic changes in lung biopsy specimens, negative microbiological, mycological and cytological analyses of the BAL fluid and exclusion of other possible causes of organizing pneumonia.
Clarithromycin (CAM) was orally administered at a dose of 500 mg twice daily for three months. Patients who did not respond or who responded only partially to the clarithromycin treatment received prednisone orally at a dose of 0.5 mg/kg of weight for six weeks, with a continuous decrease in dosage over a period of six months.
The patients were assessed every month during the treatment and re-evaluated at the end of it. Subsequently, all the patients were examined in the 3 rd and 6 th months of the first year following treatment, and then every year for 3-5 years.
Complete or nearly complete regression of COP was defined as resolution of symptoms, decreases in serum inflammatory marker concentrations and complete or nearly complete resolution of pulmonary infiltrates on CT scans.
Bronchoalveolar Lavage
Bronchoalveolar Lavage (BAL) was performed during flexible fiberoptic bronchoscopy examinations under local anesthesia in the areas involved in the disease, according to established guidelines. The distal tip of the flexible fiberoptic bronchoscope was introduced into the small bronchus. Usually 100 or 200 mL of lukewarm, sterile, isotonic saline solution were administered in 20 mL portions and immediately recovered by means of gentle manual aspiration. The total recovery volume varied from 50 to 190 mL depending on the fluid recovery rate, the patient's condition and individual tolerance of the procedure.
Cytokine Assessments
Serum concentrations of IL-1β (test sensitivity: minimum detectable level 1 pg/mL), IL-6 (test sensitivity: 1 pg/mL), IL-8 (test sensitivity: 1.5 pg/mL), and TGF-β1 (test sensitivity: 1.7 pg/mL) were assessed by the ELISA method following the manufacturer's instructions (R & D Systems Inc., Minneapolis, USA). Serum samples were taken from all the patients before and after the clarithromycin treatment, and BAL samples were collected before treatment, and 14 days after the therapy.
Five milliliters of blood and BAL-f samples were collected in serum separator tubes, allowed to clot for 30 min at 4°C, centrifuged at 4000 g for 10 min and stored in aliquots at −80°C. All measurements were done in duplicate, and the final result was the mean value of the two measurements.
Statistical Analysis
The statistical analysis was performed using STATISTICA 10 software (StatSoft Inc., Tulsa, OK, USA). Continuous unpaired variables were compared using the unpaired Student's t-test or the Mann-Whitney U-test, but for paired variables the paired Student's test and the Wilcoxon signed rank test were used. Fisher's exact test and the χ 2 test were used for proportion assessment. The Pearson r coefficient was used to measure the strength of associations between two variables. A p-value < 0.05 was considered statistically significant. All p-values are two-sided and unadjusted for multiple testing.
Results
Out of the 26 participants in the study, 22 responded to the CAM treatment and were regarded as responders (R). Partial response was noted in two patients, and two patients did not respond to the treatment. These four patients were considered non-responders (NR). The responders were younger than the non-responders, but the difference did not reach statistical significance (mean age, 55.14 ± 8.53 years vs. 63.75 ± 7.84 years; p = 0.071).
There were no significant differences between responders and non-responders in terms of sex, smoking, the duration of symptoms, the observation period or concomitant diseases, with the exception of arterial hypertension, which was found among 32% of the responders but 100% of the non-responders (p = 0.022). The characteristics of the study participants are presented in Table 1 .
During the observation period relapse was noticed in one responder and in one non-responder, 26 months and 6 months, respectively, after the end of the treatment. Both these women experienced multiple relapses. 
Clinical Manifestations
The patients commonly presented weakness (92%), cough (85%), fever (80%), weight loss (62%), dyspnea (38%), sweats (50%), chest pain (31%) and sputum expectoration (27%) ( Table 2 ). There were no significant differences between the responders and non-responders in terms of their clinical presentation, with exception of a higher frequency of sweats in non-responders (41% vs. 100%; p = 0.048).
Radiological Findings
Bilateral pulmonary lesions (96%), with air bronchograms (100%) and ground glass opacities (90%) were frequent radiological findings; nodules (50%), diffuse reticular lesions (23%), lymph node enlargement (12%) and pleural fluid (4%) were also noted. Migratory lung lesions were observed in 77% of the patients. There were no significant differences between the responders and nonresponders in terms of the radiological pattern of changes.
Laboratory Findings
All the patients had elevated erythrocyte sedimentation rates (mean: 76.82 ± 38.71 mm/h). The mean leukocyte count was 8420 ± 2710/mL, and the mean number of eosinophils was 260 ± 330 mL. Antinuclear antibody titers, rheumatoid factor, antithyroid peroxidase and antithyroglobulin antibodies were elevated in three patients (12%), one patient (4%) and three patients (12%), respectively. The responders did not differ significantly from the non-responders in any of the laboratory parameters analyzed. 
Lung Function Parameters
Spirometry data were available for all the patients, but body plethysmography and the diffusing capacity of the lungs for carbon monoxide for only 23 (89%) ( Table 2 ). The patients who did not respond to CAM had significantly decreased pulmonary function parameters in comparison to the responders: The mean FVC % of predicted was 69.0 ± 23.05 in non-responders as opposed to 101.85 ± 18.58 in responders (p = 0.006), and the FEV1 % of predicted was 73.75 ± 13.75 in non-responders, compared to 97.35 ± 13.91 (p = 0.006). The non-responders displayed obturation significantly more frequently than the responders (50% vs. 9%; p = 0.037); likewise impaired DL, CO (mean DL, CO% of predicted 59.25 ± 13.37 vs. 79.67 ± 16.97; p = 0.039).
The patients who responded to CAM had significantly higher values of oxygen tension in arterialized capillary blood (76.76 ± 8.99 mm Hg vs. 62.75 ± 4.2 mm Hg in the nonresponders; p = 0.006). Desaturation in 6MWT was observed significantly more frequently in non-responders than responders (100% vs. 9%; p = 0.018).
Bronchoalveolar Lavage
Bronchoalveolar lavage (BAL) was performed on all 26 patients. The mean percentages of macrophages, lymphocytes, eosinophils and neutrophils were 64.51% ± 24.28%, 26.3% ± 18.06%, 4.05% ± 5.75% and 6.48% ± 9.83%, respectively.
Data regarding subpopulations of lymphocytes in BAL-f were available for 16 patients. The mean ratio of CD4 + /CD8 + cells was 3.71 ± 2.66; 6 patients showed a ratio of < 1.0, and in 4 patients the ratio was over 2. BAL-f eosinophil levels between 20% and 25% were present in 2 patients, and neutrophil levels of > 10% were present in 3 patients.
Examination of the cell populations in the BAL fluid showed no significant differences in the distribution of macrophages, lymphocytes, or subpopulations of lymphocytes between the groups, but individual patients showed a wide variety of results. There were no significant differences between the responders' and non-responders' BAL profiles.
Serum Cytokines
CAM treatment was associated with significant decreases in serum concentrations of IL-6 (8.98 ± 13.26 pg/mL before treatment vs. 3.1 ± 6.95 pg/mL after treatment; p = 0.005), IL-8 (20.14 ± 25.72 pg/mL before treatment vs. 10.14 ± 6.8 pg/mL after treatment; p = 0.007) and TGF-β1 (37.89 ± 12.49 ng/mL before treatment vs. 26.49 ± 12.45 ng/mL after treatment; p = 0.001) ( Table 3 ). There was no difference between IL-1β serum concentrations before and after the treatment. Initially, the patients who responded to CAM displayed similar serum concentrations of these cytokines as the non-responders. In the responders, the median values of IL-6, IL-8 and TGF-β1 were significantly decreased after the treatment: The median for IL-6 was 8.29 ± 13.7 pg/mL before ns. -not significant. treatment vs. 1.84 ± 3.08 pg/mL after (p = 0.003); for IL-8 it was 19.86 ± 27.5 pg/mL before and 9.81 ± 6.98 pg/mL after (p = 0.036); and for TGF-β1 it was 39.14 ± 12.49 ng/mL before treatment vs. 26.12 ± 10.56 ng/mL after (p = 0.001). In the nonresponding patients the differences were not analyzed because of small number of cases. There were no significant differences between the responders and non-responders in the median values of IL-1β, IL-8 and TGF-β1 serum concentration before and after the CAM treatment, but the responders displayed significant decrease of IL-6 after the CAM treatment in comparison with the non-responders (1.84 ± 3.08 pg/mL in the responders vs. 9.97 ± 15.69 pg/mL in the non-responders; p = 0.029).
BAL-f Cytokines
CAM treatment resulted in a significant decrease in IL-6 concentration in the BAL fluid (30.56 ± 56.78 pg/mL before treatment vs. 4.53 ± 5.84 pg/mL after treatment; p = 0.036). There was no difference between IL-1β, IL8, TGF-β1 concentrations in the BAL-f before and after the treatment. The patients who responded to CAM displayed similar BAL-f concentrations of the cytokines examined as those who did not respond to CAM. The responders showed a significant decrease in the mean values of IL-6 in the BAL-f after the treatment (32.34 ± 60.65 pg/mL before and 4.13 ± 6.37 pg/mL after treatment; p = 0.018). In the non-responding patients the differences were not analyzed because of small number of cases (Table 4) .
Discussion
Beyond specific antibacterial activity, macrolides have unspecific anti-inflammatory activity, which has been used in diffuse panbronchiolitis, atopic dermatitis, asthma, bronchiectases, cystic fibrosis, bronchiolitis obliterans and inflammatory bowel diseases [16] [17] [18] [19] . The efficacy of these antibiotics in COP has been demonstrated in few studies [20] [21] and in previous research by the present authors [22] . Macrolides influence the production and release of proinflammatory cytokines [23] . It has been shown that these antibiotics inhibit the production of IL-1 and TNF-α in monocytes; IL-1, TNF-α and GM-CSF in mast cells; and IL-8, macrophage inflammatory protein-1 (MIP-1) in macrophages and lymphocytes [7, 24] . The suppressor activity of macrolides on fibroblast-like cells lowers IL-6 and IL-1 concentrations [25] . By inhibiting nuclear factor kappa B (NF-κb), macrolides decrease the expression of genes involved in the immune response (e.g. i-NOS, COX-2, TNF-α, IL-1 and IL-6) [7, 26] . Macrolides downregulate the activation and migration of neutrophils and IL-8 production, elastase activity and the neutrophil oxi dative burst [23] [24] [25] [26] .
Cai et al. showed that alveolar macrophages increased spontaneous and lipopolysaccharide-stim- ulated production of several cytokines in patients with COP, such as TNF-α, sTNFR1, sTNFR2, IL-1β, IL-6, IL-8, IL-10 IP-10 and CCL18 [7] . Partial inhibition (30-50%) of this reaction was observed when CAM or azithromycin were added. It was a dose-dependent process comparable to changes induced by dexamethasone. Additionally, a stronger inhibitory effect of CAM than azithromycin on cytokine production was revealed.
Similarly, but in a clinical situation, the present study showed a decrease of serum concentrations of inflammatory cytokines such as IL-6, IL-8, and TGF-β in the COP patients successfully treated with CAM. The patients who did not respond to treatment displayed higher levels of IL-6 in serum after the treatment than the responders. Also, successful therapy with CAM was correlated with a decrease in IL-6 concentration in BAL-f. Interleukin-6 is a pleiotropic cytokine exerting multidirectional effects on cells, and is a key regulator of defense mechanisms. Moreover, it is a stimulator of acute phase protein synthesis in the liver [28] . Overproduction of IL-6 results in a shift from acute to chronic inflammation, neutrophil recruitment, inhibition of neutrophil apoptosis and promotion of monocyte differentiation [29] . Inhibition of IL-6 production is probably one of the main mechanisms of clarithromycin's effects in COP.
Despite theoretical assumptions that IL-1 gene expression is inhibited by macrolides, the patients in the present study did not show any changes in serum or BAL-f concentrations of IL-1β in connection with the treatment [7, 10, 24] .
It has previously been reported that not all patients respond to CAM treatment [20] [21] [22] . In the present study, 15% of the patients responded only partially or did not respond to CAM treatment. The lack of CAM effect was frequently observed in more severely ill patients (those with severe respiratory impairment and lower values of blood oxygenation). In addition, the non-responders did not display a decrease of IL-6 in serum, as was noticed in the patients who responded to treatment and were assessed as healthy. There are no data regarding the correlation between response to CAM treatment and clinical status and/or pulmonary function parameters. However, studies with prednisone in COP revealed that delayed treatment, elevated levels of cholestasis enzymes and hypoxemia were correlated with relapses [30] . In the present study, two relapses were noticed during the observation period (53.08 ± 24.47 months), one in a responder, and one in a non-responder). Because of the small number of patients who relapsed, the specific factors that could have led to reactivation of the disease were not analyzed.
The present study has some limitations. It analyzed only the four cytokines thought to be the most important in the pathogenesis of COP. They represent only a small part of all the possible inflammatory mediators involved in the development of the disease. The most important limitation, however, is the small number of patients, particularly those who did not respond to treatment and in whom BAL was performed. Additionally, the levels of cytokines varied widely. These parameters influenced the power of the statistical analysis.
